May 2026 in “International Journal of Pharmaceutical Quality Assurance” PCOS causes various symptoms and needs early diagnosis and management.
May 2026 in “Journal of Clinical Oncology” Brentuximab vedotin chemotherapy can cause long-term hair loss and emotional distress.
May 2026 in “Acta Dermato Venereologica” Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
Combining platelet-rich plasma with other treatments may improve hair growth in androgenetic alopecia.
Combining platelet-rich plasma with other treatments may improve hair growth in androgenetic alopecia.
May 2026 in “Skin Appendage Disorders” Combining PRP with other treatments may improve hair growth more than PRP alone.
Lower postoperative hematocrit levels increase the risk of death within 28 days after coronary artery bypass surgery.
May 2026 in “International Journal of Research Publication and Reviews” The polyherbal hair dye is a safe, effective, and eco-friendly alternative to synthetic dyes.
April 2026 in “Journal of Cutaneous Pathology” Alopecia can be caused by multicentric reticulohistiocytosis.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
April 2026 in “The Journal of Dermatology” Vitiligo patients have higher risks of autoimmune diseases, infections, and skin cancer.
March 2026 in “Dicle Medical Journal / Dicle Tip Dergisi” Blood groups are not linked to hidradenitis suppurativa.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The natural hair dye is safe, effective, and good for scalp health.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The natural hair dye is safe, effective, and good for scalp health.
February 2026 in “Biomedicines” Off-label treatments are heavily used for alopecia areata due to limited approved options.
February 2026 in “SHILAP Revista de lepidopterología” Female Pattern Hair Loss is linked to genetics, diet, stress, and certain health conditions.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Statins do not help improve alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Statins do not help improve alopecia areata.
January 2026 in “Aesthetic Plastic Surgery” The severity of female pattern hair loss is linked to how long someone has had it, not to levels of certain nutrients or hormones.
January 2026 in “Archives of Dermatological Research” Severe COVID-19 increases the risk of hair loss.
January 2026 in “Journal of the American Academy of Dermatology” 5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
January 2026 in “Dermatologic Therapy” Combining microneedling with 5% minoxidil is a safe and effective treatment for female pattern hair loss, promoting significant hair regrowth.
December 2025 in “International Journal for Fundamental and Interdisciplinary Research in Homoeopathy.” A holistic approach combining homeopathy, Xogen therapy, and lifestyle changes may improve hair loss.
December 2025 in “International Journal of Research in Dermatology” Keratosis pilaris is common in young females, and dermoscopy helps diagnose it accurately.
December 2025 in “Archives of Dermatological Research” Topical minoxidil can cause unwanted hair growth and eye issues, especially in infants, so better education and guidelines are needed.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
December 2025 in “Actas Dermo-Sifiliográficas” Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.